FDA Takes Steps Aimed at Improving Quality, Safety and Efficacy of Sunscreens

Share on Social Media

The U.S. Food and Drug Administration today took steps aimed at improving the quality, safety, and efficacy of sunscreens as part of its implementation of new authorities for certain over-the-counter (OTC) drugs. In the short term, these new authorities essentially preserve status quo marketing conditions for these sunscreens. However, the agency today proposed revisions and updates to those requirements related to maximum sun protection factor (SPF) values, active ingredients, broad spectrum requirements, and product labeling, among other provisions.

“Sun safety is important for everyone, regardless of your skin tone. Americans can reduce risks from sun exposure with continued use of sun protection measures including broad spectrum sunscreen with SPF values of at least 15,” said Acting FDA Commissioner Janet Woodcock, M.D. “Today’s activities represent a key milestone in our implementation of transformative new authorities related to OTC drugs that will allow us to continue ensuring that sunscreens are safe and effective for frequent, life-long use and provide consumers with the protection they expect from these products. We are committed to using our new authorities to help meaningfully advance innovative, safe and effective options for consumers and secure a robust OTC marketplace.”

The 2020 Coronavirus Aid, Relief, and Economic Security (CARES) Act reformed and modernized the way sunscreens marketed without approved applications are regulated in the U.S. The Act establishes a deemed final order for sunscreens, which, along with other requirements established by the CARES Act, sets the current requirements for marketing these OTC sunscreen products. The CARES Act did not change the scientific standards for determining whether a sunscreen may be legally marketed without an approved application. OTC orders establish conditions under which the FDA permits certain OTC drugs to be marketed without approved new drug applications because they are generally recognized as safe and effective (GRASE), so long as they comply with all other applicable requirements. 

The deemed final order for sunscreens includes certain requirements about active ingredients from the 1999 final monograph regulation for OTC sunscreen products, which never took effect. It also includes labeling and effectiveness requirements from a final 2011 labeling and effectiveness testing rule

The deemed final order essentially preserves the pre-CARES status quo marketing conditions for these sunscreens, as, before CARES was passed, sunscreens were marketed according to nearly identical terms that were described in an FDA enforcement discretion policy. For this reason, the FDA believes that most sunscreens on the market are in compliance with the deemed final order. This order will remain in effect until the FDA issues another final order revising it.

The CARES Act required the FDA to issue a proposed revised order by Sept. 27, 2021. The FDA is announcing the availability of the proposed order today that the Agency is using as a vehicle to efficiently transition its ongoing consideration of the appropriate requirements for OTC sunscreens marketed without approved applications from the previous rulemaking process to this new order process.  

The provisions in today’s proposed order are therefore substantively the same as those described in the FDA’s 2019 proposed rule on sunscreens and are aimed at bringing sunscreens that are marketed without FDA-approved applications up to date with the latest science to better ensure consumers have access to safe and effective sunscreen products. For example, the order proposes to update the GRASE status for the 16 active ingredients listed in the deemed final order. It also proposes that dosage forms that are GRASE for use as sunscreens include oils, lotions, creams, gels, butters, pastes, ointments and sticks, and proposes GRASE status for spray sunscreens, subject to testing and labeling requirements. 

The order’s proposals related to SPF and broad spectrum are designed to ensure that consumers have access to sunscreens with adequate ultraviolet A rays (UVA) protection, given the growing body of data linking UVA exposure to skin cancers and other harms. The order also proposes updates to how products are labeled to make it easier for consumers to identify key product information.  

The agency will consider comments on the proposed order submitted during a 45-day public comment period before issuing a revised final order (and is considering all comments timely submitted to the 2019 proposed rule to be constructively submitted to the proposed order). The CARES Act specifies that the effective date for the revised final order cannot be earlier than one year after its issuance. 

Broad spectrum sunscreens with SPF values of at least 15 are only one element of a skin-cancer prevention strategy. Other sun protective behaviors include: wearing protective clothing that adequately covers the arms, torso and legs; wearing sunglasses and a hat that provides adequate shade to the whole head; and seeking shade whenever possible during periods of peak sunlight.

Latest News

Women In Bio (WIB) Announces Launch of 14th Chapter: WIB-Connecticut

Sea Island, GA, March 03, 2021 (GLOBE NEWSWIRE) -- Women In Bio (WIB), a national organization of professionals committed to promoting the careers, leadership and entrepreneurship of women in the life sciences, is excited to announce the launch of WIB-Connecticut, the...

Top pharma industry predictions for 2021

In many ways, the beginning of 2021 isn’t just one of the most welcome New Years of the modern era — it could also be a turning point between the pre-COVID and post-COVID worlds. Perhaps more than most other industries, the landscape of pharma was radically altered by...

DRIVEN/RI-INBRE Ignition Fund FOA – DEADLINE January 11, 2021

Funding is sparse for commercial-focused biomedical projects due to their inherent risks. The DRIVEN Accelerator Hub, an NIH/NIGMS-funded consortium serving biomedical entrepreneurs in Northeast IDeA states (https://www.drivenacceleratorhub.com/), is pleased to offer...

Slater Technology Fund-backed company to be acquired by Novartis

Slater Technology Fund-backed company to be acquired by Novartis

PROVIDENCE – The Cambridge, Mass.-based company Cadent Therapeutics has entered into an agreement to be acquired by Novartis in a deal worth up to $770 million, Slater Technology Fund announced Friday. The company was formed through a merger with the Slater Technology...

Biotech Industry News